http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Jun 2024 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/Press+Releases/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location> and <location value="LU/us.ca.berley" idsrc="xmltag.org" >BERKELEY, Calif.</location></span>, <span class="legendSpanClass"><chron>June 20, 2024</chron></span> /PRNewswire/ -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that <person value="APIN:4029759837">Stephen J. Farr</person>, PhD, begins today as Chief Executive Officer (CEO).</p> <p><person>Dr. Farr</person> served as President and CEO of <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> from 2015 until its acquisition by UCB in 2022. He transformed <span value="ACORN:5010023982" idsrc="xmltag.org" >Zogenix</span> into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and <location value="LC/jp" idsrc="xmltag.org" >Japan</location>. <person>Dr. Farr</person> initially served as <span http://www.streetinsider.com/PRNewswire/Regel+Therapeutics+Appoints+Stephen+J.+Farr+as+New+Chief+Executive+Officer/23376660.html Thu, 20 Jun 2024 08:00:00 -0400 A.21695839 A.50100239 O.03791136 O.28804538 STDY http://www.streetinsider.com/SEC+Filings/Form++15-12B+++++SteadyMed+Ltd.+++++++++++++++++++++++/14592796.html si-local-file:///var/storage/secattach/20180910/14592796.html http://www.streetinsider.com/SEC+Filings/Form++15-12B+++++SteadyMed+Ltd.+++++++++++++++++++++++/14592796.html Mon, 10 Sep 2018 13:59:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+OrbiMed+Advisors+Israel+II+Ltd/14589026.html si-local-file:///var/storage/secattach/20180907/14589026.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+OrbiMed+Advisors+Israel+II+Ltd/14589026.html Fri, 07 Sep 2018 17:06:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++SC+13DA+++SteadyMed+Ltd.+++++++++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/14588960.html si-local-file:///var/storage/secattach/20180907/14588960.html http://www.streetinsider.com/SEC+Filings/Form++SC+13DA+++SteadyMed+Ltd.+++++++++++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/14588960.html Fri, 07 Sep 2018 16:59:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++SteadyMed+Ltd.+++++++++++++++++++++++/14586195.html si-local-file:///var/storage/secattach/20180907/14586195.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++SteadyMed+Ltd.+++++++++++++++++++++++/14586195.html Fri, 07 Sep 2018 06:03:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++SteadyMed+Ltd.+++++++++++++++++++++++/14586192.html si-local-file:///var/storage/secattach/20180907/14586192.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++SteadyMed+Ltd.+++++++++++++++++++++++/14586192.html Fri, 07 Sep 2018 06:02:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++SteadyMed+Ltd.+++++++++++++++++++++++/14586181.html si-local-file:///var/storage/secattach/20180907/14586181.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++SteadyMed+Ltd.+++++++++++++++++++++++/14586181.html Fri, 07 Sep 2018 06:01:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Bank+Keith/14575334.html si-local-file:///var/storage/secattach/20180904/14575334.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Bank+Keith/14575334.html Tue, 04 Sep 2018 19:46:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+STARK+BRIAN+JAY/14575332.html si-local-file:///var/storage/secattach/20180904/14575332.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+STARK+BRIAN+JAY/14575332.html Tue, 04 Sep 2018 19:45:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+SteadyMed+Investors%2C+LLC/14575329.html si-local-file:///var/storage/secattach/20180904/14575329.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+SteadyMed+Investors%2C+LLC/14575329.html Tue, 04 Sep 2018 19:44:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Ginor+Ron/14575327.html si-local-file:///var/storage/secattach/20180904/14575327.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Ginor+Ron/14575327.html Tue, 04 Sep 2018 19:43:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+FARR+STEPHEN+J/14575325.html si-local-file:///var/storage/secattach/20180904/14575325.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+FARR+STEPHEN+J/14575325.html Tue, 04 Sep 2018 19:42:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+RIGBY+JONATHAN/14575320.html si-local-file:///var/storage/secattach/20180904/14575320.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+RIGBY+JONATHAN/14575320.html Tue, 04 Sep 2018 19:41:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Nassif+David+W./14575318.html si-local-file:///var/storage/secattach/20180904/14575318.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Nassif+David+W./14575318.html Tue, 04 Sep 2018 19:40:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Cermak+Elizabeth/14575315.html si-local-file:///var/storage/secattach/20180904/14575315.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Cermak+Elizabeth/14575315.html Tue, 04 Sep 2018 19:38:00 -0400 STDY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Huffman+Donald+D/14575314.html si-local-file:///var/storage/secattach/20180904/14575314.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SteadyMed+Ltd.++++++++++++For%3A+Aug+30++Filed+by%3A+Huffman+Donald+D/14575314.html Tue, 04 Sep 2018 19:37:00 -0400 STDY